Atrys Health, S.A. (BME:ATRY)

Spain flag Spain · Delayed Price · Currency is EUR
2.670
-0.025 (-0.93%)
May 18, 2026, 4:00 PM CET
Market Cap204.57M -8.7%
Revenue (ttm)144.31M +7.0%
Net Income-100.30M
EPS-1.32
Shares Out75.91M
PE Ration/a
Forward PE46.61
Dividendn/a
Ex-Dividend Daten/a
Volume46,872
Average Volume54,953
Open2.695
Previous Close2.695
Day's Range2.630 - 2.695
52-Week Range2.480 - 3.590
Beta0.55
RSI38.21
Earnings DateJun 22, 2026

About Atrys Health

Atrys Health, S.A., together with its subsidiaries, provides diagnostic services and medical treatments in Spain, Portugal, and Latin America. It operates through Diagnosis, Oncology, and Preventive Medicine segments. The company offers integrated diagnostics services comprising structural and molecular pathology, genetics, and nuclear medicine diagnosis; online medical imaging in the fields of radiology and cardiology; oncology treatment services, such as chemotherapy, immunotherapy, radiotherapy, and brachytherapy; second opinion and genetic ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2007
Employees 758
Stock Exchange Madrid Stock Exchange
Ticker Symbol ATRY
Full Company Profile

Financial Performance

In 2025, Atrys Health's revenue was 144.31 million, an increase of 7.00% compared to the previous year's 134.88 million. Losses were -100.30 million, 215.7% more than in 2024.

Financial Statements

News

Atrys Health Earnings Call Transcript: Q2 2024

Revenue grew 5% to €107.4M and adjusted EBITDA rose 24.6% to €25.2M, driven by operational efficiencies and strong growth in oncology and prevention. Guidance for 2024 is reaffirmed, with net profit expected to break even in 2025.

1 year ago - Transcripts